What If OPA1 Genetic Testing Is Negative For ADOA?

It can be incredibly frustrating to have classic symptoms of Autosomal Dominant Optic Atrophy (ADOA) only to have your genetic test come back negative for OPA1. The direct answer is that a negative standard OPA1 test does not mean you do not have the condition. Standard genetic sequencing can easily miss large structural changes in the gene ^[1]. Your doctor’s next step will typically be to order specialized testing (like MLPA) to look for hidden OPA1 mutations, assuming it wasn’t part of your initial test. If that is also negative, they will likely broaden the search to look at other genes that can cause identical symptoms. Because this process can be complex, working with a genetic counselor is highly recommended to help you navigate testing options and understand the results.

Why Standard Testing Misses OPA1 Mutations

Standard genetic testing (often called Sanger sequencing or basic Next-Generation Sequencing) is like reading a book letter by letter to look for spelling mistakes. While this is excellent at finding small errors, it is notoriously bad at noticing if an entire paragraph or chapter is missing ^[1].

Because ADOA is typically caused by haploinsufficiency—meaning one copy of your OPA1 gene isn’t working properly—a missing chunk of the gene (a deletion) is a common culprit ^[2]. Standard sequencing technologies frequently underestimate the frequency of these large OPA1 deletions due to technical limitations ^[1][3]. Additionally, standard tests usually only look at the gene’s primary coding regions (exons), potentially missing deeply buried mutations in the non-coding areas (introns) that disrupt how the gene is assembled ^[4].

Note: Many modern multi-gene panels now routinely include “Deletion/Duplication analysis.” It is worth checking your lab report or asking your doctor if this was already performed as part of your initial test.

Step 1: Deeper Specialized OPA1 Testing

If your clinical symptoms—such as bilateral vision loss and thinning of the optic nerve—strongly point to ADOA, and your initial test did not look for large deletions, your specialist will likely pursue more advanced testing for the OPA1 gene:

• MLPA (Multiplex Ligation-dependent Probe Amplification): This specialized test is specifically designed to detect Copy Number Variations (CNVs), which are the large deletions or duplications that standard sequencing misses ^[5]. For patients strongly suspected of having ADOA who test negative on standard panels, MLPA is considered a crucial diagnostic tool ^[6].
• Whole Genome or RNA Sequencing: If MLPA is negative, whole genome sequencing or transcript analysis (RNA sequencing) can be used to search for “deep intronic variants” that disrupt the normal processing of the OPA1 gene ^[4][5].

Be prepared that advanced genetic testing can take anywhere from several weeks to a few months to return results.

Step 2: Exploring Alternative Genes

If deep testing rules out OPA1 completely, your medical team will expand the search. Several other genes cause isolated optic nerve atrophy or conditions with overlapping symptoms. Modern multi-gene panels or Whole Exome Sequencing (WES) can scan for these alternatives, which typically yields a diagnosis in about 30% of previously unexplained cases ^[7].

Alternative culprits often include:

• Mitochondrial DNA (mtDNA): Because ADOA affects the mitochondria (the energy factories of cells), doctors often check the mitochondrial genome to rule out Leber Hereditary Optic Neuropathy (LHON), another major cause of inherited vision loss ^[8][9].
• AFG3L2 and SPG7: Mutations in these genes can cause isolated optic atrophy that looks identical to OPA1-related ADOA ^[10][11].
• WFS1: While often associated with Wolfram syndrome, certain WFS1 mutations cause only isolated dominant optic atrophy ^[12][13].
• SSBP1 and ACO2: These genes are vital for mitochondrial health. Mutations here damage the optic nerve by making the cells vulnerable to stress, similar to how OPA1 mutations work ^[14][15].
• MFN2: Specific mutations in this gene can present primarily with thinning of the retinal nerve fiber layer, mirroring classic ADOA ^[16][17]. You may sometimes see this referred to as Charcot-Marie-Tooth disease type 6 (CMT6).

A Note on Anxiety and Other Symptoms: Seeing that these alternative genes are sometimes linked to other health conditions (like diabetes, hearing loss, or mobility issues) can be terrifying. However, finding a mutation in one of these genes does not automatically mean you will develop those other conditions. Many specific mutations cause only vision loss, and your genetic counselor can explain exactly what your specific genetic change means for your future health.

What If All Genetic Tests Are Negative?

It is entirely possible to go through advanced testing and still not find a genetic match. If this happens, you are not in diagnostic limbo. ADOA and inherited optic neuropathies can be diagnosed clinically based on your symptoms, family history, and eye exams (like an OCT scan showing specific nerve thinning).

Science simply hasn’t discovered every single genetic mutation that causes optic atrophy yet. A negative genetic test does not invalidate your symptoms or your diagnosis, and your medical team will continue to manage your care, monitor your vision, and support you just as they would if you had a confirmed OPA1 mutation.